Evidence map›Paper›PMID 31388620›Full record

ArticleVideoGIE : an official video journal of the American Society for Gastrointestinal Endoscopy2019

Alternative approach to hemostatic particle spraying for treatment of GI bleeding by the use of cross-platform devices.

Abdul Haseeb, Martin L Freeman, Stuart K Amateau

Abstract read
In one paragraph

Article in VideoGIE : an official video journal of the American Society for Gastrointestinal Endoscopy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Abdul HaseebDivision of Gastroenterology and Hepatology, Department of Medicine, University of Minnesota Medical Center, Minneapolis, Minnesota, USA.
Martin L FreemanDivision of Gastroenterology and Hepatology, Department of Medicine, University of Minnesota Medical Center, Minneapolis, Minnesota, USA.
Stuart K AmateauDivision of Gastroenterology and Hepatology, Department of Medicine, University of Minnesota Medical Center, Minneapolis, Minnesota, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

aimsGI bleeding is a leading cause of morbidity and mortality in the United States, with an estimated 20,000 deaths per year. Some subgroups of patients show refractory recurrent bleeding despite standard endoscopic therapy. The U.S. Food and Drug Administration has recently approved a hemostatic spray for clinical use in nonvariceal bleeding. Despite its efficacy, not all endoscopy units have access to this spray, at times because of cost. Our aim was to determine the safety and efficacy of a plant-based hemostatic particle spray in nonvariceal GI bleeding by use of a cross-platform setup.

methodWe present 3 cases in which plant-based particle spray was used for hemostasis with a cross-platform delivery system. Conventional therapies failed in the first 2 cases, and in the third case hemostatic particle spray was used as a primary therapy.

resultsSuccessful immediate hemostasis was achieved in all 3 patients. No immediate adverse events or recurrence of bleeding was noted.

conclusionsPlant-based hemostatic particle spray is safe and effective as a temporizing measure in refractory ulcer and postnecrosectomy cavity bleeding. Further studies are needed to establish the safety and comparative efficacy of plant-based hemostatic powder. The cross-platform system used here for plant-based hemostatic particle spray presents a less-expensive alternative in selected cases.

Indexed as

FDA, U.S. Food and Drug AdministrationUSD, U.S. dollars

Identifiers

PMID31388620
PMCPMC6675922

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.